Ropes & Gray represented Ironwood Pharmaceuticals, Inc. in the completion of a $150 million debt refinancing, announced Sept. 26. Issuance of the new 8.375 percent notes is subject to full redemption of Ironwood’s existing Linaclotide PhaRMA 11 percent notes due 2024. The principal balance on the existing PhaRMA notes upon announcement of the transaction was approximately $143 million.
Headquartered in Cambridge, Mass., Ironwood is a commercial biotechnology company that is advancing a pipeline of innovative medicines in areas of significant unmet need, including irritable bowel syndrome with constipation/chronic idiopathic constipation, uncontrolled gout, refractory gastroesophageal reflux disease, and vascular and fibrotic diseases.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.